venBio Global Strategic Fund IV, L.P. bought $6.5M of ATTO
owner at Attovia Therapeutics, Inc.. 382,352 shares at an average of $17.00, traded Aug 6, 2026, filed Aug 10, 2026.
Score components
- +12Role10% owner
- +25Trade size$6.5M at market
- +3Relative to holdingsHoldings up 10%
- 0Price contextNo price history yet
- +15Cluster6 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-26-003548, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | CConversion Common Stock | +2,311,870 | - | - | 2,311,870 | Aug 10, 2026 |
| Aug 6, 2026 | CConversion Common Stock | +821,998 | - | - | 3,133,868 | Aug 10, 2026 |
| Aug 6, 2026 | CConversion Common Stock | +665,147 | - | - | 3,799,015 | Aug 10, 2026 |
| Aug 6, 2026 | POpen-market purchase Common Stock | +382,352 | $17.00 | $6.5M | 4,181,367 | Aug 10, 2026 |
| Aug 6, 2026 | CConversion Series A Preferred Stockderivative | -21,477,273 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | CConversion Series B Preferred Stockderivative | -7,636,362 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | CConversion Series C Preferred Stockderivative | -6,179,219 | $0.00 | $0 | 0 | Aug 10, 2026 |
Related signals
Other insiders at Attovia Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 61Notable | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $2.3M 105,807 shares | -124% | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 56Moderate | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $10M 585,000 shares | - | |
| 61Notable | Attovia Therapeutics, Inc. | Goldman Sachs Group Inc other | $2.3M 105,807 shares | -124% | |
| 63Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $10M 585,000 shares | - | |
| 68Notable | Attovia Therapeutics, Inc. | Colin Walsh director | $2.3M 105,807 shares | -124% | |
| 52Moderate | Attovia Therapeutics, Inc. | Redmile Group, LLC owner | $10M 600,000 shares | +77% | |
| 53Moderate | Attovia Therapeutics, Inc. | Sanofi owner | $5.1M 300,000 shares | +38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.